Fast and Reproducible Vascular Neointima Formation in the Hamster Carotid Artery: Effects of Trapidil and Captopril

Summary

Neointima formation was induced in the hamster carotid artery by mechanical intraluminal injury with a catheter covered with roughened dental cement. Neointimal thickening occurred as early as 7 days after denudation and further increased during the next 1 to 2 weeks. Proliferation indices of smooth muscle cells (SMCs) showed the highest proportion of proliferating cells in the media and neointima respectively 1 and 5 days after the vascular injury. Transmission and scanning electron microscopy of damaged carotid artery sections as well as immuno-histochemical stainings of von Willebrand factor (vWF) confirmed that reendothelialization was progressive and already complete on day 14, at which time the neointima formation was almost complete.

In order to pharmacologically characterize this model further, the effects on neointima formation of trapidil (triazolopyrimidine), a platelet-derived growth factor (PDGF) antagonist, and captopril, an angiotensin converting enzyme inhibitor, were investigated. Trapidil administered orally twice daily at total doses of 25, 50 and 100 mg/kg/day, started 3 days prior to infliction of injury and up to 7 or 14 days after the catheterization, significantly reduced neointima formation. Captopril administered orally three times daily at a total dose of 100 mg/kg/day, equally reduced neointima formation, with 100 mg/kg/day trapidil being more effective than 100 mg/kg/day captopril 7 days after injury. When the treatment by either one of these drugs was arrested on day 7, neointima formation resumed quickly.

The hamster appears to be a small, reproducible and fast model for the study of SMC proliferation, requiring only relatively small amounts of experimental drugs. The model furthermore is sensitive to substances known to reduce neointima formation in other animal models.

• References

• 1 Gruetzing AR, Senning A, Siegenthaler WE. Nonoperative dilation of coronary artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61-68
• 2 Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990; 15: 1667-1687
• 3 Ellis SG, Roubin G, King G, Douglas S, Weintraub G, Cox WS. Angiographic and clinical predictors of acute closure after native vessel coronary angiography. Circulation 1988; 77: 372-379
• 4 Holmes DR, Holubkov R, Vlietstra RE, Kelsey SF, Reeder GS, Dorros G, Williams DO, Cowley MJ, Faxon DP, Kent KM. Comparison of complications during percutaneous transluminal coronary angioplasty from 19771981 and from 1985-1986 the National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol 1988; 12: 1149-1155
• 5 Bates ER, McGillem MJ, Mickelson JK, Pitt B, Mancini GB J. A monoclonal antibody to the platelet receptor GPIIb/IIIa (7E3) prevents acute thrombosis in a canine model of coronary angioplasty. Circulation 1988; 78 Suppl (Suppl. 02) 11-289
• 6 Matsuno H, Uematsu T, Takiguchi Y, Wada K, Nakashima M. Effect of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and the vascular patency after thrombolysis by tissue-type plasminogen activator. BrJ Pharmacol 1993; 106: 533-542
• 7 Schwartz L, Bourassa MG, L’Esperance J, Aldridge HE, Kazim F, Salva- tori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole and the prevention of restenosis after percutaneous transluminal angioplasty. N Engl J Med 1988; 318: 1714-1719
• 8 Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol 1991; 17: 77B-88B
• 9 Ferns GA A, Raines EW, Sprugel KH, Montani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253: 1129-1137
• 10 Kuratsu J, Ushino Y. Antiproliferative effect of trapidil, a platelet-derived growth factor antagonist, on a glioma cell line in vitro. J Neurosurg 1990; 73: 436-440
• 11 Liu MW, Roubin GS, Robinson KA, Black AJ R, Hearn JA, Siegel RJ, King III SB. Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 1990; 81: 1089-1093
• 12 Powell JS, Muller RK M, Rouge M, Kuhn H, Hefti F, Baumgartner HR. The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol 1990; 16 Suppl (Suppl. 04) S42-S49
• 13 Powell JS, Clozel JP, Muller RK, Hefti F, Hosang N, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-188
• 14 Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivan- hoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL. Willerson J and on behalf of the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-886
• 15 Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994; 90: 2203-2206
• 16 Okamoto S, Inden M, Sesuda M, Konoshi T, Nakano T. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1992; 123: 1439-1445
• 17 Rubin D, Antonaccio MJ, Horovitz ZP. Captopril (SQ 14,225) (D-mer- capto-2-methylpropranoyl-L-proline): a novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent. Prog Cardiovasc Dis 1978; 21: 183-194
• 18 Matsuno H, Uematsu T, Nakashima M. Photochemically induced thrombosis model in the rat femoral artery and evaluation of effect of heparin and tissue-type plasminogen activator in this model. J Pharmacol Meth 1991; 25: 303-318
• 19 Linder V, Olson NE, Clowes AW, Reidy MA. Inhibition of smooth muscle cell proliferation in injured rat arteries. J Clin Invest 1992; 90: 2044-2049
• 20 Miettinen M, Lindenmayer AE, Chanbel A. Endothelial cell markers CD31, CD34 and BNH9 antibody to H- and Y-antigen. Evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with vWF Modem Pathology 1994; 7: 82-90
• 21 Clowes AW, Reidy M, Clowes MM. Mechanisms of stenosis after injury. Lab Invest 1983; 49: 208-214
• 22 Dzau VJ, Gibbons GH, Pratt KE. Molecular mechanisms of vascular renin- angiotensin system in myointimal hyperplasia. Hypertension 1991; 78: 100-105
• 23 Mazurov AV, Menshikov MY, Leytin VL, Tkachuk VA, Repin VS. Decrease of platelet aggregation and spreading via inhibition of the cAMP phosphodiesterase by trapidil. FEBS Lett 1984; 172: 167-171